A citation-based method for searching scientific literature


List of co-cited articles
47 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity






Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
439
20

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
422
20

Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.
Mohammad Katout, Hong Zhu, Jessica Rutsky, Parthy Shah, Robert D Brook, Jixin Zhong, Sanjay Rajagopalan. Am J Hypertens 2014
86
20

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
20

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
20

Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan. Diabetes Care 2014
211
20


DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
300
20

Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.
Raymond V Oliva, George L Bakris. J Am Soc Hypertens 2014
137
20


Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.
Yutaka Seino, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. Curr Med Res Opin 2014
38
20

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Nobuya Inagaki, Shin-Ichi Harashima, Nobuko Maruyama, Yutaka Kawaguchi, Maki Goda, Hiroaki Iijima. Cardiovasc Diabetol 2016
45
20

Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
C D Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson. Diabetes Obes Metab 2015
30
20

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
A I Adler, I M Stratton, H A Neil, J S Yudkin, D R Matthews, C A Cull, A D Wright, R C Turner, R R Holman. BMJ 2000
20

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
J P H Wilding, G Charpentier, P Hollander, G González-Gálvez, C Mathieu, F Vercruysse, K Usiskin, G Law, S Black, W Canovatchel,[...]. Int J Clin Pract 2013
231
20

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
365
20

Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Kyung-Ah Han, Suk Chon, Choon Hee Chung, Soo Lim, Kwan-Woo Lee, SeiHyun Baik, Chang Hee Jung, Dong-Sun Kim, Kyong Soo Park, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2018
20
20

Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Preman Kumarathurai, Christian Anholm, Andreas Fabricius-Bjerre, Olav W Nielsen, Ole Kristiansen, Sten Madsbad, Steen B Haugaard, Ahmad Sajadieh. J Hypertens 2017
23
20

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
57
20

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Hans J Woerle, Uli C Broedl. Diabetes Care 2013
259
20

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G Terra,[...]. Diabetes Obes Metab 2018
82
20

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.
Michael Nauck, Manfredi Rizzo, Andrew Johnson, Heidrun Bosch-Traberg, Jesper Madsen, Bertrand Cariou. Diabetes Care 2016
88
20

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Julio Rosenstock, Juan Frias, Dénes Páll, Bernard Charbonnel, Raluca Pascu, Didier Saur, Amanda Darekar, Susan Huyck, Harry Shi, Brett Lauring,[...]. Diabetes Obes Metab 2018
85
20

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
338
20

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
92
20



Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Linong Ji, Jianhua Ma, Hongmei Li, Traci A Mansfield, Caroline L T'joen, Nayyar Iqbal, Agata Ptaszynska, James F List. Clin Ther 2014
109
20


Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes.
Marcel H A Muskiet, Erik Jm van Bommel, Daniël H van Raalte. Lancet Diabetes Endocrinol 2016
24
20

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Melanie Davies, Thomas R Pieber, Marie-Louise Hartoft-Nielsen, Oluf K H Hansen, Serge Jabbour, Julio Rosenstock. JAMA 2017
167
20

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
295
20

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial.
Kohei Kaku, Arihiro Kiyosue, Yuri Ono, Toshihiko Shiraiwa, Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch-Traberg, Yutaka Seino. J Diabetes Investig 2016
13
20



Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Michaela Diamant, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, Michael Trautmann. Lancet 2010
324
20

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.
Jean-Pierre Gutzwiller, Stefan Tschopp, Andreas Bock, Carlos E Zehnder, Andreas R Huber, Monika Kreyenbuehl, Heike Gutmann, Jürgen Drewe, Christoph Henzen, Burkhard Goeke,[...]. J Clin Endocrinol Metab 2004
271
20


Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
720
20

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Julio Rosenstock, Dale Allison, Andreas L Birkenfeld, Thalia Marie Blicher, Srikanth Deenadayalan, Jacob Bonde Jacobsen, Pierre Serusclat, Rafael Violante, Hirotaka Watada, Melanie Davies. JAMA 2019
112
20


Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Keith C Ferdinand, Joseph L Izzo, Jisoo Lee, Leslie Meng, Jyothis George, Afshin Salsali, Leo Seman. Circulation 2019
33
20


Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
277
20

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
Marcus Lind, Irl B Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Bo Ahrén, Ole Torffvit, Stig Attvall, Magnus Ekelund, Karin Filipsson, Bengt-Olov Tengmark,[...]. BMJ 2015
52
20

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Carol H Wysham, Julio Rosenstock, Marion L Vetter, Fang Dong, Peter Öhman, Nayyar Iqbal. Diabetes Obes Metab 2018
19
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.